Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Alemtuzumab-Related Thyroid Dysfunction in a Phase 2 Trial of Patients with Relapsing-Remitting Multiple Sclerosis.
Vitamin D3 transactivates the zinc and manganese transporter SLC30A10 via the Vitamin D receptor.
Differing trends in the incidence of vascular comorbidity in MS and the general population.
Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation.
Acorda Therapeutics announces Hatch-Waxman extension of AMPYRA® (dalfampridine) sustained-release formulation patent
Social Media Representation of Chronic Cerebrospinal Venous Insufficiency Intervention for Multiple Sclerosis.
Vitamin D as an Early Predictor of Multiple Sclerosis Activity and Progression.
Mast cell inflammasome activity in the meninges regulates EAE disease severity.
Epigenetics of Multiple Sclerosis: An Updated Review.
Immuno-modulatory Properties of a Quinolin-2-(1H)-on-3-carboxamide Derivative: Relevance in Multiple Sclerosis.
Sanofi Reports Positive Top-Line Results from First Phase 3 Study of Alemtuzumab (Lemtrada) in Multiple Sclerosis
Effects of Interferon β-1a and Interferon β-1b Monotherapies on Selected Serum Cytokines and Nitrite Levels in Patients with Relapsing-Remitting Multiple Sclerosis: A 3-Year Longitudinal Study.
Artesunate Ameliorates Experimental Autoimmune Encephalomyelitis by Inhibiting Leukocyte Migration to the Central Nervous System.
Mechanisms of action for treatments in multiple sclerosis: Does a heterogeneous disease demand a multi-targeted therapeutic approach?
Kaposi sarcoma in a fingolimod-treated patient with multiple sclerosis.
Extended interval dosing of natalizumab in multiple sclerosis.
Urinary incontinence in multiple sclerosis: prevalence, severity and impact on patients' quality of life.
[Immunomodulation and neuroprotection in optic neuritis].
Effects of fumarates on circulating and CNS myeloid cells in multiple sclerosis.
Therapy Optimization in Multiple Sclerosis: A cohort study of therapy adherence and risk of relapse.
Influence of infection on exacerbations of multiple sclerosis.
Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo--final report.
Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study.
Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).
Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use.

Pages